This webinar is now complete, thank you for your interest. Please visit our events page to keep up with the latest webinars and events.
Date and time: Thursday 21st October 2021 | 1400 GMT.
This webinar will introduce and describe the benefits of pharmaceutical crystallisation process development, how to approach different types of pharmaceutical crystallisation processes using process analytical technologies (PAT), and highlight the benefits of developing a controlled crystallisation on downstream processes such as filtration, drying and milling.
Topics in this presentation include:
- Crystallisation Process objectives
- Solubility screening & MSZW determination
- Methods of crystallisation process (Cooling, Antisolvent addition, Evaporation and Seeding)
- Monitoring crystallisation process using Process Analytical Technology (PAT)
- Downstream Process Development & Particle Engineering (Filtration, Drying, milling and PMT)
Dr. Solomon Abebe
Analytical Team Leader – Almac Sciences
Solomon works at Almac Group as Crystallisation and Downstream Processes Development Team Leader.
His skills include different approaches of developing crystallisation and downstream processes for the manufacture of solid API as well as the ability to build mathematical models using various statistical data analysis techniques such as chemometrics and process simulating techniques such as Dynochem.
His educational background is a combination in a variety of engineering disciplines: BEng in Mechanical Engineering, MSc in Process Engineering and a PhD in Particle Science and Engineering degrees from Middlesex University, Cranfield University and University of Leeds, UK respectively.
Solomon has worked in various projects in prestigious pharmaceutical companies such as Pfizer as Material Scientist (UK), Novartis as a Senior Scientist (Switzerland), GlaxoSmithKline (UK) as a Process Analytical Technology (PAT) engineer and currently at Almac Group (UK) as team leader.
Solomon boasts several accomplishments, but nothing beats involvement in a blockbuster medicine Seebri and Ultibro Breezhalers for the treatment of chronic obstructive pulmonary disease (COPD) for which he was a core member of the team who developed the API process.